The CMTM6 gene helps cells keep PD-L1, a surface signal that tells immune cells to ease off, available where it is needed. This gene plays an important role in keeping immune reactions balanced. If the CMTM6 gene does not work properly, PD-L1 levels may drop, which can change how strongly immune cells respond and may influence inflammation or how some cancers interact with the immune system.
What is a gene?
Genes are stretches of DNA that carry instructions cells use to make molecules or manage activities in the body. Some genes provide the directions for producing proteins, which do much of the work inside cells. Others mostly regulate when specific activities happen, where they occur, and how active they are. Taken together, genes affect how the body grows and works, and they can influence your response to food, stress, and medicines. More detail is available in the LearnHub.
Overview
CMTM6Gene function
What if the gene works
The CMTM6 gene helps cells control immune signaling by keeping the PD-L1 protein on their surface. This supports balanced immune responses and how the body distinguishes normal tissues from threats.
Risk
What if the gene does not work
When the CMTM6 gene works less well, cells may struggle to keep enough PD-L1, a surface protein that helps control immune signaling. Milder and more severe variants can reduce this support to different degrees.
Treatment
What does that mean for your treatment
No CMTM6-specific treatment or management approach is currently established for people with a pathogenic variant in the CMTM6 gene. Researchers are studying the CMTM6 gene as a possible cancer marker and drug target, especially because it may shape how tumors interact with the immune system.
Gene function
What if the gene works
In your body, the CMTM6 gene helps cells manage immune signals at their surface. It is best known for controlling how cells handle PD-L1, a protein that can calm immune activity when needed. This everyday role supports balanced communication between cells and the immune system.
The CMTM6 gene helps keep PD-L1 available on the cell surface. This lets cells send a measured slow-down signal to immune cells as part of normal immune control.
Inside cells, CMTM6 guides PD-L1 through endosomes (small sorting compartments) so it can be reused instead of removed too soon. This helps maintain a steady surface supply of the protein.
By shaping how PD-L1 is handled, the CMTM6 gene plays a part in how immune signals are regulated between cells. This is one of the main ways the CMTM6 gene works in the immune system.
What is a variant?
A genetic variant is a slight change in a gene’s DNA sequence. These changes are common and help explain normal differences among people, including appearance, metabolism, and the way the body responds to environmental influences. Many variants do not have any noticeable effect and are simply part of natural genetic variation. Sometimes, though, a variant changes how a gene works more significantly and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
CMTM6 gene variants can change the protein's shape, stability, or movement to the cell surface, which may weaken how it helps keep partner proteins such as PD-L1 from being broken down. In practice, how CMTM6 gene variants affect protein function ranges from mild changes that partly reduce activity to more disruptive variants that leave very little working protein. This spectrum can lead to different degrees of cellular effect.
How variants are linked to conditions
At present, the CMTM6 gene does not have a broadly confirmed link to a specific health condition, and research on how CMTM6 gene variants are linked to conditions is still developing. If you have a reported variant in the CMTM6 gene, your doctor or genetic counselor can place it in the context of your own health and family history.
A variant is not necessarily a diagnosis
Genetic variants are a common and normal feature of human biology in the general population. Most have no direct impact on health and simply reflect natural human diversity. For many genes, carrying a variant associated with a condition indicates a possible link rather than a confirmed diagnosis, especially when several genes and environmental factors are involved. In some situations, though, a single well-characterized variant in a specific gene is enough to confirm a diagnosis.
Are there things that can increase or change my risk?
There is not yet broadly confirmed evidence on specific factors that increase or reduce health risk related to the CMTM6 gene itself. If a change in CMTM6 is found on genetic testing, its meaning usually depends on the exact change and the wider clinical picture, so personal risk is best discussed with a doctor or genetic counselor.
Inheritance of CMTM6 variants
For families trying to understand how CMTM6 gene variants are inherited, there is not yet a broadly confirmed disease-specific inheritance pattern linked to this gene. Research on CMTM6 is still developing, so inheritance details may become clearer over time. The CMTM6 gene is located on chromosome 3, which is an autosome, so each person inherits one copy from their mother and one copy from their father.
What does my CMTM6 result mean for my family?
There is not yet a broadly confirmed inherited condition clearly tied to the CMTM6 gene in the way seen with some other genes. That means a CMTM6 result usually does not by itself give a clear, established prediction about which relatives may also be affected or carry the same change. Family meaning depends on the exact result and why testing was done.
Genetic information
Genetic testing
How you find out about variants
Genetic testing for CMTM6 variants usually uses a blood or saliva sample. A lab reads the DNA in the CMTM6 gene and looks for changes in its sequence, either on a gene panel or as part of broader exome or genome testing. Results may show whether a variant is present.
When should I consider getting a genetic test?
There is not yet a broadly established, CMTM6-specific reason to get genetic testing in routine care. Decisions about testing are best made with a doctor or genetic counselor, based on your personal health history, family history, and the reason testing is being considered.
A genetic result is only one part of your health story
A genetic result can provide useful insight, but how much it explains varies with the condition and the kind of variant found. Over time, many factors, including lifestyle, environment, age, and medical history, influence how the body functions. For some conditions, particularly those shaped by many genes, genetic information offers context rather than certainty and is most helpful when viewed together with other parts of care. In other situations, a genetic result can give a clear answer. In areas like medication response, genetic results can also help put a person’s individual experience in context.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. Some people break down a drug more slowly or more quickly, while others may be more or less likely to get the intended benefit or certain side effects. This is a common part of human biology and helps explain why the same treatment can feel different from one person to another.
What is Pharmacogenetics?
Pharmacogenetics is the area of study that examines how genetic differences affect the way people respond to medications. It focuses on links between genes and drugs to help explain why the same treatment can work differently from one person to another. For many medicines, genes can influence how powerfully a drug works or how the body handles it. This information can support more informed, more personalized treatment decisions. More detail on this topic is available in the LearnHub.
Drugs influenced by the CMTM6 gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in guiding medicine choice or dosing, so general medication questions are best discussed with your doctor. Researchers are studying whether CMTM6 may affect how some cancers respond to immune-based treatments, but this has not become part of routine care.
History
The CMTM6 gene entered the research literature in the 2000s, when scientists were mapping a group of related genes called the CMTM family. Early work placed it within a newly recognized gene family that linked features of chemokines and membrane proteins. Building on this early work, scientists uncovered more about the gene. A major turning point came in 2017, when independent CRISPR screening studies identified the CMTM6 gene as an important regulator of PD-L1, a protein already central to cancer immunotherapy research. That finding quickly drew broad interest from cancer biologists and immunology teams. Since then, the CMTM6 gene has become a regular part of studies exploring how tumors interact with the immune system and why responses to immune based treatments can differ between people.